Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 859.80 INR
Change Today 0.00 / 0.00%
Volume 0.0
RBXY On Other Exchanges
Natl India
As of 7:40 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

ranbaxy laboratories ltd (RBXY) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/15 - 869.70
52 Week Low
09/26/14 - 551.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ranbaxy laboratories ltd (RBXY) Related Businessweek News

View More BusinessWeek News

ranbaxy laboratories ltd (RBXY) Details

Ranbaxy Laboratories Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical products. The company offers generics, differentiated products, over-the-counter products, anti-retrovirals, active pharmaceutical ingredients, and intermediates. Its products are used for the treatment in various therapy areas, including anti-infectives, cardiovascular, pain and musculoskeletal, central nervous system, gastrointestinal, respiratory, anti-retrovirals, dermatology, orthopaedics, nutritionals, urology, and diabetes. The company offers a portfolio of approximately 500 molecules in the forms of tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Ranbaxy Laboratories Limited operates in India, Europe, North America, the Asia Pacific, and Africa. The company was founded in 1961 and is headquartered in New Delhi, India. Ranbaxy Laboratories Limited is a subsidiary of Daiichi Sankyo Company, Ltd.

15,300 Employees
Last Reported Date: 07/1/14
Founded in 1961

ranbaxy laboratories ltd (RBXY) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: --
President, Global Head of Technical Operation...
Total Annual Compensation: --
President and Chief Financial Officer
Total Annual Compensation: --
President and Head of Global Research & Devel...
Total Annual Compensation: --
Chief Executive Officer of Indian Operations
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

ranbaxy laboratories ltd (RBXY) Key Developments

Sun Pharma-Ranbaxy Deal Obtains Indian Competition Regulator's Final Approval Upon Divestment to Emcure Pharma

Competition Commission of India has given final clearance to the Sun Pharmaceutical-Ranbaxy Laboratories merger following the divestment of seven overlapping drugs to Emcure Pharmaceuticals (India). The brands that were divested, representing only 1% of the combined entity's revenues in India, include Tamlet (tamsulosin hydrochloride), Rosuvas EZ (rosuvastatin), Eligard (leuprolide acetate), Terlibax (terlipressin), Olanex F (olanzapine), Raciper L (esomeprazole + levosulpiride), and Trioolvance (olmesartan medoxomil + amlodipine + hydrochlorothiazide).Emcure reportedly declined Sun Pharma and Ranbaxy's CCI-ordered transitional support to ensure continued supply of the products towards relevant markets. Indian anti-trust regulatory approval comes four days after Sun Pharma and Ranbaxy were granted final authorisation from the US Federal Trade Commission (FTC) following the merger's successful conditional minocycline tablets divestment to Torrent Pharmaceuticals (India), amid monopoly concerns within the US market. The CCI found Emcure, an active marketing competitor in India, to be the best fit to acquire the divestment products, with sufficient financial resources and manufacturing capability to fully benefit from the acquisition of the chronic therapy drugs.

US FDA Cancels Approval for Two Ranbaxy Drugs in United States

Approvals granted to Ranbaxy by the US Food and Drug Administration (USFDA) for marketing generic versions of two blockbuster medicines and the 180-day marketing exclusivity stand cancelled. The DC Federal Court in the US has upheld the USFDA's decision to revoke tentative approvals given to the company for the generic versions of AstraZeneca's digestive disorder drug Nexium and Roche's antiviral Valcyte. In November last year, Ranbaxy had sued USFDA over revoking an approval to sell the generic drugs.

Ranbaxy Labs Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015

Ranbaxy Labs Ltd. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBXY:IN 859.80 INR 0.00

RBXY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RBXY.
View Industry Companies

Industry Analysis


Industry Average

Valuation RBXY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RANBAXY LABORATORIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at